Decoding the Multi-Target Anticancer Pharmacology of Alpinia galanga: Integrating Redox Vulnerability, Apoptotic Signaling, and Translational Barriers

Cancer remains one of the main causes of death worldwide. The development of drug resistance, systemic toxicity, and poor therapeutic selectivity continues to limit the efficacy of conventional treatments. Multi-target therapeutic agents that can modulate complex oncogenic networks are gaining increasing interest among natural products. Alpinia galanga (L.) Willd. is a medicinal plant that is a promising source of bioactive compounds with high anticancer potential. This review summarizes the current evidence on the anticancer activities of A. galanga extracts and its major phytochemicals, including 1′-acetoxychavicol acetate (ACA), 1′-acetoxyeugenol acetate (AEA), galangin, chrysin, pinocembrin, and related flavonoids. Mechanistically, these compounds modulate various hallmarks of cancer by modulating oxidative stress, apoptosis, autophagy, cell-cycle arrest, mitochondrial dysfunction, inflammatory signaling, and metastatic pathways, particularly NF-κB, PI3K/Akt, MAPK, and p53-associated networks. Recent findings have shed light on the emerging roles of A. galanga compounds in overcoming resistance to targeted therapy, suppressing immune evasion through efferocytosis, remodeling the tumor microenvironment, and augmenting chemosensitivity and immunotherapeutic responses. Importantly, advances in nanotechnology-based formulations, such as lipid nanocarriers, exosome-mediated delivery systems, and biomimetic nanovaccines, have greatly improved the translational potential of galangin and other phytochemicals by improving their bioavailability, tumor targeting, and immune activation. This review also provides a critical discussion of the current pharmacokinetic limitations, translational challenges, and future opportunities for integrating A. galanga-derived compounds in precision oncology and combination-based cancer therapies. Collectively, the available evidence suggests that A. galanga is a platform with mechanistic versatility and clinical promise for next-generation anticancer therapeutics.